Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
oleh: Jamie A. Kmak, Nikita Agarwal, Yuting He, Andreas M. Heilmann, Vincent A. Miller, Jeffrey S. Ross, Sumanta Kumar Pal, Siraj M. Ali, Deepak Kilari
| Format: | Article |
|---|---|
| Diterbitkan: | Karger Publishers 2020-04-01 |
Deskripsi
Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN inactivating mutation in the patient’s tumor. After being heavily pretreated, the patient showed stable disease on everolimus, a PI3K-Akt-mTOR pathway inhibitor.